Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Sisram, a Fosun Pharma Device Company, Staging a $200 Million Hong Kong IPO

publication date: Sep 5, 2017

Sisram Medical, an Israeli company that makes laser-based aesthetic devices, will raise up to $200 million by conducting an IPO on the Hong Kong Exchange. Sisram is a subsidiary of Shanghai Fosun Pharma. In 2013, Fosun teamed up with Chindex, which would become a Fosun subsidiary, and a private equity firm to pay $240 million for 96% of Israel's Alma Lasers. The holding company is named Sisram. The IPO will value Sisram at up to $800 million, with Fosun owning a 66% stake. More details....

Stock Symbols: (SHA: 600196; HK: 02196)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.